Fortress Biotech (FBIO) Free Cash Flow Growth (1y) (2011 - 2025)
Powered by 
Analysis
Fortress Biotech (FBIO) Free Cash Flow Growth (1y) (2011 - 2025) Analysis & Trends
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | FCF Growth (1y) (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 141.52 Bn | 133.66 Bn | 2.84 Bn | 9.25% |
| 2 | Regeneron Pharmaceuticals | 86.69 Bn | 78.69 Bn | 3.93 Bn | -38.10% |
| 3 | Argenx Se | 64.63 Bn | 59.45 Bn | 1.37 Bn | - |
| 4 | Moderna | 59.30 Bn | 54.16 Bn | 52.00 Mn | 38.94% |
| 5 | Revolution Medicines | 44.41 Bn | 44.41 Bn | - | - |
| 6 | BeOne Medicines | 40.45 Bn | 35.35 Bn | 1.53 Bn | 96.00% |
| 7 | Alnylam Pharmaceuticals | 35.29 Bn | 31.98 Bn | 992.69 Mn | 152.82% |
| 8 | Royalty Pharma | 28.44 Bn | 27.60 Bn | - | 31.57% |
| 9 | Insmed | 27.55 Bn | 26.39 Bn | 358.27 Mn | 58.53% |
| 10 | Fortress Biotech | 86.15 Mn | -110.42 Mn | 12.58 Mn | - |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Dec 31, 2025 | 2.81% |
| Sep 30, 2025 | 67.26% |
| Jun 30, 2025 | -18.62% |
| Mar 31, 2025 | 22.94% |
| Dec 31, 2024 | 63.08% |
| Sep 30, 2024 | -11.23% |
| Jun 30, 2024 | 30.25% |
| Mar 31, 2024 | 41.29% |
| Dec 31, 2023 | 27.06% |
| Sep 30, 2023 | 62.08% |
| Jun 30, 2023 | 20.19% |
| Mar 31, 2023 | 10.29% |
| Dec 31, 2022 | -17.91% |
| Sep 30, 2022 | -99.72% |
| Jun 30, 2022 | -15.72% |
| Mar 31, 2022 | -116.78% |
| Dec 31, 2021 | -91.90% |
| Sep 30, 2021 | 5.19% |
| Jun 30, 2021 | -93.67% |
| Mar 31, 2021 | 0.89% |